Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on LTR Pharma.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX gains as lithium, iron ore miners dazzle; copper and gold stocks extend rally
News
ASX Small Caps Lunch Wrap: Anyone else feeling a little forgetful this morning?
Health & Biotech
ASX Health Stocks: Argenica flies over 15pc after FDA grants Rare Pediatric Disease Designation
Health & Biotech
LTR Pharma commences dosing for pivotal erectile dysfunction study of SPONTAN
Health & Biotech
ASX stocks striving to inject youthfulness into an aging world population
News
Closing Bell: Local markets ride commodities higher after a blow to US confidence on Friday
Health & Biotech
ASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pc
Health & Biotech
LTR Pharma firms up study for erectile dysfunction with patient recruitment
News
ASX Small Caps Lunch Wrap: Is this the weaponised AI we’re supposed to be scared of?
Health & Biotech
ASX Health Stocks: LTP is recruiting for patients to try its erection spray
News
ASX Quarterly Wrap: LTR Pharma firms up, Wisr expands margins and revenue growth
IPO Watch
Raised and risen: LTR Pharma floated to top of Aussie IPO pool in 2023, ahead of LU7
IPO Watch
IPO Wrap: Hot IPOs in 2024 from around the world; and a look at the final 2023 scorecard for ASX
News
ASX Small Caps and IPO Weekly Wrap: A Benchmark bonanza, but harder to pick than a broken nose
News
